These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 11569495)

  • 1. Roots of clinical resistance to STI-571 cancer therapy.
    Hochhaus A; Kreil S; Corbin A; La Rosée P; Lahaye T; Berger U; Cross NC; Linkesch W; Druker BJ; Hehlmann R; Gambacorti- Passerini C; Corneo G; D'Incalci M
    Science; 2001 Sep; 293(5538):2163. PubMed ID: 11569495
    [No Abstract]   [Full Text] [Related]  

  • 2. Roots of clinical resistance to STI-571 cancer therapy.
    Barthe C; Cony-Makhoul P; Melo JV; Mahon JR
    Science; 2001 Sep; 293(5538):2163. PubMed ID: 11567109
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.
    Gorre ME; Mohammed M; Ellwood K; Hsu N; Paquette R; Rao PN; Sawyers CL
    Science; 2001 Aug; 293(5531):876-80. PubMed ID: 11423618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer research. Why some leukemia cells resist STI-571.
    Marx J
    Science; 2001 Jun; 292(5525):2231-3. PubMed ID: 11423629
    [No Abstract]   [Full Text] [Related]  

  • 5. New-age drug meets resistance.
    McCormick F
    Nature; 2001 Jul; 412(6844):281-2. PubMed ID: 11460142
    [No Abstract]   [Full Text] [Related]  

  • 6. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
    Chien JH; Tang JL; Chen RL; Li CC; Lee CP
    Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of Bcr-Abl point mutations in chronic myeloid leukemia patients in chronic phase before imatinib treatment is not predictive of response.
    Agirre X; Fontalba A; Andreu EJ; Odero MD; Larráyoz MJ; Montiel C; Calasanz MJ; Fernández-Luna JL; Prósper F
    Haematologica; 2003 Dec; 88(12):1425-6. PubMed ID: 14687999
    [No Abstract]   [Full Text] [Related]  

  • 8. Increasing the BCR-ABL expression levels and/or the occurrence of ABL point mutations does not always predict resistance to Imatinib Mesylate in BCR-ABL positive acute lymphoblastic leukemia.
    Grammatico S; Elia L; Peluso AL; Pedace L; Matarazzo M; Vitale A; Rago A; Pane F; Foà R; Cimino G
    Leuk Res; 2009 Jul; 33(7):e73-4. PubMed ID: 19108887
    [No Abstract]   [Full Text] [Related]  

  • 9. [STI571: the resistance organizes!].
    Jeanteur P
    Bull Cancer; 2001 Sep; 88(9):819. PubMed ID: 11642306
    [No Abstract]   [Full Text] [Related]  

  • 10. A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib.
    Gruber FX; Hjorth-Hansen H; Mikkola I; Stenke L; Johansen T
    Leukemia; 2006 Nov; 20(11):2057-60. PubMed ID: 17008892
    [No Abstract]   [Full Text] [Related]  

  • 11. Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to Imatinib.
    Piazza RG; Magistroni V; Gasser M; Andreoni F; Galietta A; Scapozza L; Gambacorti-Passerini C
    Leukemia; 2005 Jan; 19(1):132-4. PubMed ID: 15510211
    [No Abstract]   [Full Text] [Related]  

  • 12. Chronic myeloid leukemia and BCR/ABL signal pathways are not associated with AKT1 pleckstrin homology domain (E17K) mutations.
    He Y; Zheng J; Hu Y; Xiao H; Liu J; Li X; Du W; Chen X; Hu Y; Huang S
    Eur J Haematol; 2010 Jan; 84(1):87-8. PubMed ID: 19744127
    [No Abstract]   [Full Text] [Related]  

  • 13. Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
    Tanaka R; Kimura S
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1387-98. PubMed ID: 18759691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploiting oxidative damage to overcome resistance.
    Karp JE; Smith BD
    Leuk Res; 2006 Oct; 30(10):1213-4. PubMed ID: 16564572
    [No Abstract]   [Full Text] [Related]  

  • 15. [Mechanism and overcome against drug resistance to imatinib for treatment of chronic myeloid leukemia].
    Tauchi T; Oyashiki K
    Gan To Kagaku Ryoho; 2011 May; 38(5):749-53. PubMed ID: 21702118
    [No Abstract]   [Full Text] [Related]  

  • 16. Cancer biology: summing up cancer stem cells.
    Huntly BJ; Gilliland DG
    Nature; 2005 Jun; 435(7046):1169-70. PubMed ID: 15988505
    [No Abstract]   [Full Text] [Related]  

  • 17. Dasatinib in chronic myelogenous leukemia.
    Chu SC; Tang JL; Li CC
    N Engl J Med; 2006 Sep; 355(10):1062-3; author reply 1063-4. PubMed ID: 16960978
    [No Abstract]   [Full Text] [Related]  

  • 18. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
    Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
    Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary imatinib resistance associated with an aberrant bcr-abl fusion gene.
    Janssen JJ; Hochhaus A; van Oostveen JW; Waisfisz Q; Schuurhuis GJ; Ossenkoppele GJ
    Leukemia; 2004 May; 18(5):1020-1. PubMed ID: 15014529
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.